JP2024034027A - Chinese medicine extract formulation - Google Patents
Chinese medicine extract formulation Download PDFInfo
- Publication number
- JP2024034027A JP2024034027A JP2022138015A JP2022138015A JP2024034027A JP 2024034027 A JP2024034027 A JP 2024034027A JP 2022138015 A JP2022138015 A JP 2022138015A JP 2022138015 A JP2022138015 A JP 2022138015A JP 2024034027 A JP2024034027 A JP 2024034027A
- Authority
- JP
- Japan
- Prior art keywords
- chinese herbal
- extract
- ephedra
- herbal extract
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 238000009472 formulation Methods 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 title abstract description 20
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 26
- 239000003765 sweetening agent Substances 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000000346 sugar Nutrition 0.000 claims abstract description 9
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 7
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 7
- 229940124530 sulfonamide Drugs 0.000 claims abstract description 7
- -1 sulfonamide compounds Chemical class 0.000 claims abstract description 7
- 150000008163 sugars Chemical class 0.000 claims abstract description 6
- 229920001542 oligosaccharide Chemical class 0.000 claims abstract description 5
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 5
- 239000012676 herbal extract Substances 0.000 claims description 92
- 238000002360 preparation method Methods 0.000 claims description 45
- 241000411851 herbal medicine Species 0.000 claims description 38
- 241000218671 Ephedra Species 0.000 claims description 31
- 241000475481 Nebula Species 0.000 claims description 11
- 239000010175 Yi-Gan San Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 241000207965 Acanthaceae Species 0.000 claims description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 6
- 239000005715 Fructose Substances 0.000 claims description 6
- 229930091371 Fructose Natural products 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 244000184734 Pyrus japonica Species 0.000 claims description 5
- 239000004376 Sucralose Substances 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 235000012907 honey Nutrition 0.000 claims description 5
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 5
- 235000019408 sucralose Nutrition 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- SVBWNHOBPFJIRU-UHFFFAOYSA-N 1-O-alpha-D-Glucopyranosyl-D-fructose Natural products OC1C(O)C(O)C(CO)OC1OCC1(O)C(O)C(O)C(O)CO1 SVBWNHOBPFJIRU-UHFFFAOYSA-N 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical class CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims description 4
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 4
- 229960004903 invert sugar Drugs 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 4
- 229960000511 lactulose Drugs 0.000 claims description 4
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019204 saccharin Nutrition 0.000 claims description 4
- 229940081974 saccharin Drugs 0.000 claims description 4
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 4
- NMXLJRHBJVMYPD-IPFGBZKGSA-N trehalulose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O)CO[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NMXLJRHBJVMYPD-IPFGBZKGSA-N 0.000 claims description 4
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 claims description 3
- 241000245165 Rhododendron ponticum Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 208000024891 symptom Diseases 0.000 abstract description 17
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract description 15
- 230000002496 gastric effect Effects 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 7
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940010454 licorice Drugs 0.000 description 7
- 241000202807 Glycyrrhiza Species 0.000 description 6
- 241000736199 Paeonia Species 0.000 description 6
- 235000006484 Paeonia officinalis Nutrition 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 241000208422 Rhododendron Species 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 240000002045 Guettarda speciosa Species 0.000 description 3
- 235000001287 Guettarda speciosa Nutrition 0.000 description 3
- 244000273928 Zingiber officinale Species 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 244000080208 Canella winterana Species 0.000 description 2
- 235000008499 Canella winterana Nutrition 0.000 description 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 2
- 240000000513 Santalum album Species 0.000 description 2
- 235000008632 Santalum album Nutrition 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229940017545 cinnamon bark Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003445 sucroses Chemical class 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 241000092897 Angelica japonica Species 0.000 description 1
- 235000015701 Artemisia arbuscula Nutrition 0.000 description 1
- 235000002657 Artemisia tridentata Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000005733 Raphanus sativus var niger Nutrition 0.000 description 1
- 240000001970 Raphanus sativus var. sativus Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000269796 Seriola quinqueradiata Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、漢方エキス製剤に関する。より具体的には、本発明は、上部消化管症状の副作用が低減された漢方エキス製剤に関する。 The present invention relates to Chinese herbal extract preparations. More specifically, the present invention relates to a Chinese herbal extract formulation with reduced side effects of upper gastrointestinal symptoms.
漢方薬は、一般的に西洋薬に比べて副作用が少ないといわれているが、医薬品である以上、副作用が無いわけではない(非特許文献1)。漢方薬による副作用の中で最も多いのが、胃もたれ等の消化器症状である(非特許文献2、3)。特に、漢方薬に使用される生薬の中でも、マオウ、ジオウ、トウキ、センキュウは、消化器症状を起こしやすい(非特許文献4、5)。 Chinese herbal medicines are generally said to have fewer side effects than Western medicines, but since they are pharmaceuticals, they are not free from side effects (Non-Patent Document 1). The most common side effects caused by Chinese herbal medicines are gastrointestinal symptoms such as heavy stomach pain (Non-patent Documents 2 and 3). In particular, among the crude drugs used in Chinese herbal medicine, ephedra, rhododendron, asperium, and nebula tend to cause gastrointestinal symptoms (Non-patent Documents 4, 5).
このような消化器症状の副作用への対処としては、服用のタイミングを食後に変更することが一般的である(非特許文献5)。 To deal with such side effects of gastrointestinal symptoms, it is common to change the timing of administration to after meals (Non-Patent Document 5).
上述のように、服用のタイミングを食後に変更することは、漢方薬による消化器症状の副作用を低減するための対処の1つであるが、漢方エキス製剤の効果を最大化することはできなくなる。漢方エキス製剤の効果を最大化する方法は、服用のタイミングを空腹時とし、且つ、水に溶いて服用するというものである。一方で、医薬品の効果のレベルと副作用のレベルとは一般的に正相関することに鑑みると、漢方エキス製剤を空腹時に水に溶いて服用しても副作用を低減することは本質的に困難である。 As mentioned above, changing the timing of administration to after meals is one way to reduce the side effects of Chinese herbal medicines on gastrointestinal symptoms, but it will not be possible to maximize the effects of Chinese herbal extract preparations. The method of maximizing the effects of Chinese herbal extract preparations is to take them on an empty stomach and to dissolve them in water. On the other hand, considering that there is generally a positive correlation between the level of effectiveness and the level of side effects of medicines, it is essentially difficult to reduce side effects even if Chinese herbal extract preparations are dissolved in water and taken on an empty stomach. be.
そこで、本発明は、用時に水に溶いて服用する漢方エキス製剤について、空腹時に服用しても、消化器症状、具体的には上部消化器症状を低減できる製剤処方を提供することを目的とする。 Therefore, an object of the present invention is to provide a Chinese herbal extract formulation that can be dissolved in water and taken before use, and can reduce gastrointestinal symptoms, specifically upper gastrointestinal symptoms, even when taken on an empty stomach. do.
本発明者らが鋭意検討を行ったところ、用時に水に溶いて服用する漢方エキス製剤に、所定の甘味料を配合することで、空腹時に服用しても上部消化器症状を低減できることを新たに見出した。本発明は、この知見に基づいて、更に検討を重ねることにより完成したものである。 The inventors of the present invention have conducted extensive research and have discovered that by adding a prescribed sweetener to a Chinese herbal extract preparation that is dissolved in water and taken before use, it is possible to reduce upper gastrointestinal symptoms even when taken on an empty stomach. I found it. The present invention was completed through further studies based on this knowledge.
即ち、本発明は、下記に掲げる態様の発明を提供する。
項1. 漢方エキスと、塩素化糖、スルホンアミド化合物、単糖、二糖、及びオリゴ糖からなる群より選択される甘味料とを含み、水に溶いて服用する、漢方エキス製剤。
項2. 前記漢方エキスが、センキュウ、トウキ、ジオウ、及び/又はマオウを含む漢方のエキスである、項1に記載の漢方エキス製剤。
項3. 前記漢方エキスが、四物湯、独活葛根湯、及び/又は抑肝散のエキスである、項1又は2に記載の漢方エキス製剤。
項4. 前記甘味料が、スクラロース、アセスルファム塩、サッカリン及びその塩、サイクラミン酸及びその塩、グルコース、フルクトース、はちみつ、異性化糖、転化糖、スクロース、マルトース、ラクトース、ラクツロース、トレハロース、パラチノース、並びにトレハルロースからなる群より選択される、項1~3のいずれかに記載の漢方エキス製剤。
項5. 前記漢方エキス100重量部に対する前記甘味料の含有量が、0.05~2重量部である、項1~4のいずれかに記載の漢方エキス。
項6. 前記漢方エキスの抽出に用いられた原生薬中のセンキュウ、トウキ、ジオウ、及びマオウの総量100重量部に対する前記甘味料の含有量が、0.01~2.5重量部である、項2~5のいずれかに記載の漢方エキス。
項7. 1回当たりの用量が、漢方エキスの抽出に用いられた原生薬中のセンキュウ、トウキ、ジオウ、及びマオウの総量で1.5~6gである、項2~6のいずれかに記載の漢方エキス。
That is, the present invention provides the inventions of the following aspects.
Item 1. A Chinese herbal extract preparation containing a Chinese herbal extract and a sweetener selected from the group consisting of chlorinated sugars, sulfonamide compounds, monosaccharides, disaccharides, and oligosaccharides, which is dissolved in water and taken.
Item 2. Item 2. The Chinese herbal extract formulation according to Item 1, wherein the Chinese herbal extract is a Chinese herbal extract containing nebula, acanthus, sperum, and/or ephedra.
Item 3. Item 3. The Chinese herbal extract preparation according to item 1 or 2, wherein the herbal medicine extract is an extract of Shimotsuto, Dokkatsu Kakkonto, and/or Yokukansan.
Item 4. The sweetener consists of sucralose, acesulfame salt, saccharin and its salt, cyclamic acid and its salt, glucose, fructose, honey, isomerized sugar, invert sugar, sucrose, maltose, lactose, lactulose, trehalose, palatinose, and trehalulose. The Chinese herbal extract preparation according to any one of Items 1 to 3, selected from the group.
Item 5. Item 5. The Chinese herbal extract according to any one of Items 1 to 4, wherein the content of the sweetener is 0.05 to 2 parts by weight based on 100 parts by weight of the Chinese herbal extract.
Item 6. Item 2~, wherein the content of the sweetener is 0.01 to 2.5 parts by weight with respect to 100 parts by weight of the total amount of Nebula japonica, Ephedra, Ephedra, and Ephedra in the original herbal medicine used to extract the Chinese herbal extract. 5. The Chinese herbal extract according to any one of 5.
Section 7. The Chinese herbal extract according to any one of items 2 to 6, wherein the dose per dose is 1.5 to 6 g of the total amount of Ephedra, Ephedra, Ephedra, and Ephedra in the original medicine used for extracting the Chinese herbal extract. .
本発明によれば、用時に水に溶いて服用する漢方エキス製剤について、空腹時に服用しても、消化器症状、具体的には上部消化器症状を低減できる製剤処方が供される。 According to the present invention, a Chinese herbal extract preparation that is dissolved in water and taken before use is provided with a formulation that can reduce gastrointestinal symptoms, specifically upper gastrointestinal symptoms, even when taken on an empty stomach.
本発明の漢方エキス製剤は、漢方エキス及び所定の甘味料を含有し、水に溶いて飲用することを特徴とする。以下、本発明の漢方エキス製剤について詳述する。 The Chinese herbal extract preparation of the present invention is characterized in that it contains a Chinese herbal extract and a predetermined sweetener, and is dissolved in water and drunk. Hereinafter, the Chinese herbal extract preparation of the present invention will be described in detail.
漢方エキス
本発明で用いられる漢方エキスは、特に限定されるものではない。本発明の漢方エキス製剤は上部消化器症状の副作用の低減効果に優れるため、当該副作用を特に起こしやすい生薬を含む漢方のエキスであっても、効果的に当該副作用を低減することができる。このような観点から好適な漢方エキスとして、センキュウ、トウキ、ジオウ、及び/又はマオウを含む漢方のエキスが挙げられる。本発明で用いられる漢方エキスの特に好ましい例としては、四物湯、独活葛根湯、及び抑肝散のエキスが挙げられる。これらの漢方エキスは、1種を単独で用いてもよいし、複数種の組み合わせで用いてもよい。
Chinese Herbal Extract The Chinese herbal extract used in the present invention is not particularly limited. Since the Chinese herbal extract preparation of the present invention is excellent in reducing side effects of upper gastrointestinal symptoms, it is possible to effectively reduce the side effects even if the Chinese herbal extract contains herbal medicines that are particularly likely to cause these side effects. From this point of view, suitable Chinese herbal extracts include extracts of Chinese herbal medicines containing nebula, acanthus, argentina, and/or ephedra. Particularly preferred examples of Chinese herbal extracts used in the present invention include extracts of Shimotsuto, Dokkatsu Kakkonto, and Yokukansan. These Chinese herbal extracts may be used alone or in combination.
独活葛根湯は、カッコン、ケイヒ、シャクヤク、マオウ、ドクカツ、ショウキョウ、ジオウ、タイソウ、及びカンゾウからなる混合生薬である。独活葛根湯エキスの製造に用いられる生薬調合物を構成する生薬の混合比としては特に制限されないが、例えば、カッコン2.5~5重量部、ケイヒ1.5~3重量部、シャクヤク1.5~3重量部、マオウ1~2重量部、ドクカツ1~2重量部、ショウキョウ0.1~2重量部、ジオウ2~4重量部、タイソウ0.5~2重量部、及びカンゾウ0.5~2重量部が挙げられる。四物湯は、シャクヤク、ジオウ、センキュウ、及びトウキからなる混合生薬である。四物湯エキスの製造に用いられる生薬調合物を構成する生薬の混合比としては特に制限されないが、例えば、シャクヤク1.5~5重量部、ジオウ1.5~5重量部、センキュウ1.5~5重量部、及びトウキ1.5~5重量部が挙げられる。抑肝散は、トウキ、チョウトウコウ、センキュウ、ビャクジュツ、ブクリョウ、サイコ、及びカンゾウからなる混合生薬である。抑肝散エキスの製造に用いられる生薬調合物を構成する生薬の混合比としては特に制限されないが、例えば、トウキ1.5~3重量部、チョウトウコウ1.5~3重量部、センキュウ1.5~3重量部、ビャクジュツ2~4重量部、ブクリョウ2~4重量部、サイコ1~5重量部、及びカンゾウ0.75~1.5重量部が挙げられる。 Dokkatsu Kakkonto is a herbal medicine mixture consisting of kakkon, keihi, peony, ephedra, dokukatsu, ginger, rhododendron, radish, and licorice. The mixing ratio of the herbal medicines constituting the herbal medicine preparation used for manufacturing Dokatsu Kakkonto extract is not particularly limited, but for example, 2.5 to 5 parts by weight of kakkon, 1.5 to 3 parts by weight of cinnamon bark, and 1.5 parts of peony. ~3 parts by weight, 1 to 2 parts by weight of ephedra, 1 to 2 parts by weight of doku cutlet, 0.1 to 2 parts by weight of ginger, 2 to 4 parts by weight of Japanese sagebrush, 0.5 to 2 parts by weight of Japanese radish, and 0.5 parts of licorice ~2 parts by weight. Shimotsuto is a herbal medicine mixture consisting of peonies, rhododendrons, nebula, and acanthus. The mixing ratio of the herbal medicines constituting the herbal medicine preparation used for the production of the Shimotsuto extract is not particularly limited, but for example, 1.5 to 5 parts by weight of Peony, 1.5 to 5 parts by weight of Rhododendron, and 1.5 parts by weight of Cucumber. -5 parts by weight, and 1.5 to 5 parts by weight of Japanese amberjack. Yokukansan is a herbal medicine mixture consisting of Chinese trumpet, Choutōkō, Senkyu, Byakujutsu, Bukryō, Saiko, and Licorice. The mixing ratio of the herbal medicines constituting the herbal medicine preparation used to produce the Yokukansan extract is not particularly limited, but for example, 1.5 to 3 parts by weight of Angelica asparagus, 1.5 to 3 parts by weight of Oriental chinensis, 1. 5 to 3 parts by weight, 2 to 4 parts by weight of sandalwood, 2 to 4 parts by weight of blackberry, 1 to 5 parts by weight of licorice, and 0.75 to 1.5 parts by weight of licorice.
本発明の漢方エキス製剤において、漢方エキスは、漢方エキスの濃縮液の形態で含まれていてもよいし、漢方エキスの乾燥物の形態で含まれていてもよい。漢方エキスの濃縮液とは、漢方エキスと溶媒(例えば、漢方エキスの抽出に用いた抽出溶媒)とを含み、濃縮エキスに含まれる漢方エキス濃度(乾燥エキス換算量)が、その漢方の煎じ薬に含まれる漢方エキス濃度(乾燥エキス換算量)より高められている又は服用時に希釈することを要する程度に高められているものをいう。漢方エキスの乾燥物は、漢方エキスの濃縮液からさらに溶媒が除去されたものをいう。 In the Chinese herbal extract formulation of the present invention, the Chinese herbal extract may be contained in the form of a concentrated liquid of the Chinese herbal extract, or may be contained in the form of a dried herbal extract. A concentrated liquid of herbal medicine extract contains a herbal medicine extract and a solvent (for example, the extraction solvent used to extract the herbal medicine extract), and the concentration of the herbal medicine extract (converted amount of dry extract) contained in the concentrated extract is equal to that of the decoction of the herbal medicine. The concentration of the Chinese herbal extract (in terms of dry extract) is higher than that contained in the herbal extract, or the concentration is increased to the extent that it is necessary to dilute it before taking it. A dried herbal extract is a concentrated herbal extract from which the solvent has been further removed.
漢方エキスの濃縮液は、漢方処方に従った生薬調合物を抽出処理し、得られた抽出液を濃縮することにより得ることができる。抽出処理に使用される抽出溶媒としては、特に限定されず、水又は含水エタノール、好ましくは水が挙げられる。抽出処理方法としては、生薬調合物に対して、約10~20倍量の抽出溶媒を加え、40~100℃、50~100℃、60~100℃、80~100℃、又は90~100℃程度で1~3時間程度撹拌して抽出する方法が挙げられる。濃縮方法としては特に限定されず、例えば、減圧下濃縮法、膜濃縮法、加熱濃縮法が挙げられる。また、漢方エキスの乾燥物は、漢方エキスの濃縮液を乾燥処理することにより得ることができる。乾燥処理の方法としては特に限定されず、例えば、フリーズドライ法、エキスの濃度を高めた軟エキスに適当な吸着剤(例えば無水ケイ酸、デンプン等)を加えて吸着末とする方法、スプレードライ法等が挙げられる。 A concentrated liquid of Chinese herbal extract can be obtained by extracting a crude drug preparation according to a Chinese herbal prescription and concentrating the obtained extract. The extraction solvent used in the extraction process is not particularly limited, and includes water or aqueous ethanol, preferably water. As an extraction treatment method, approximately 10 to 20 times the amount of extraction solvent is added to the crude drug preparation, and the mixture is heated at 40 to 100°C, 50 to 100°C, 60 to 100°C, 80 to 100°C, or 90 to 100°C. An example of this is a method of stirring for about 1 to 3 hours at a moderate temperature for extraction. The concentration method is not particularly limited, and includes, for example, a concentration method under reduced pressure, a membrane concentration method, and a heating concentration method. Moreover, a dried product of a Chinese herbal extract can be obtained by drying a concentrated liquid of a Chinese herbal extract. The drying method is not particularly limited, and examples include freeze-drying, a method of adding an appropriate adsorbent (for example, silicic anhydride, starch, etc.) to a soft extract with increased concentration to form an adsorbent powder, and spray drying. Laws, etc. can be cited.
本発明の漢方エキス製剤中の漢方エキスの含有量(乾燥エキス換算量)としては特に限定されず、漢方エキス製剤の剤型により異なりうるが、例えば5~25重量%、好ましくは10~20重量%が挙げられる。 The content of the Chinese herbal extract (in terms of dry extract) in the Chinese herbal extract preparation of the present invention is not particularly limited and may vary depending on the dosage form of the Chinese herbal extract preparation, but for example, 5 to 25% by weight, preferably 10 to 20% by weight. % is mentioned.
所定の甘味料
本発明で用いられる甘味料は、塩素化糖、スルホンアミド化合物、単糖、二糖、及びオリゴ糖からなる群より選択される。
Selected Sweeteners The sweeteners used in the present invention are selected from the group consisting of chlorinated sugars, sulfonamide compounds, monosaccharides, disaccharides, and oligosaccharides.
塩素化糖の具体例としては、スクラロースが挙げられる。スルホンアミド化合物としては、アセスルファム塩(カリウム塩、カルシウム塩、アンモニウム塩等)、サッカリン及びその塩(ナトリウム塩、カリウム塩等)、サイクラミン酸及びその塩(ナトリウム塩、カリウム塩等)が挙げられる。 A specific example of chlorinated sugar is sucralose. Examples of the sulfonamide compound include acesulfame salts (potassium salt, calcium salt, ammonium salt, etc.), saccharin and its salts (sodium salt, potassium salt, etc.), and cyclamic acid and its salts (sodium salt, potassium salt, etc.).
単糖としては、グルコース、フルクトース、及びそれらの混合物が挙げられ、当該混合物としては、はちみつ、異性化糖、転化糖が挙げられる。二糖としては、スクロース、マルトース、ラクトース、ラクツロース、トレハロース、及びスクロース異性体が挙げられ、スクロース異性体としては、パラチノース、トレハルロースが挙げられる。オリゴ糖としては、カップリングシュガー、フラクトオリゴ糖が挙げられる。 Examples of monosaccharides include glucose, fructose, and mixtures thereof, and examples of the mixtures include honey, high-fructose sugar, and invert sugar. Disaccharides include sucrose, maltose, lactose, lactulose, trehalose, and sucrose isomers, and sucrose isomers include palatinose and trehalulose. Examples of oligosaccharides include coupling sugars and fructooligosaccharides.
これらの甘味料は、1種を単独で用いてもよいし、複数種を組み合わせて用いてもよい。これらの甘味料の中でも、上部消化器症状の副作用の低減効果を高める観点から、好ましくは、塩素化糖、スルホンアミド化合物、単糖、二糖が挙げられ、より好ましくは、スクラロース、アセスルファム塩、サッカリン及びその塩、サイクラミン酸及びその塩、グルコース、フルクトース、はちみつ、異性化糖、転化糖、スクロース、マルトース、ラクトース、ラクツロース、トレハロース、パラチノース、並びにトレハルロースが挙げられ、さらに好ましくは、スクラロース、アセスルファムカリウム、グルコース、フルクトース、はちみつ、スクロースが挙げられる。 These sweeteners may be used alone or in combination. Among these sweeteners, from the viewpoint of increasing the effect of reducing side effects of upper gastrointestinal symptoms, preferable examples include chlorinated sugars, sulfonamide compounds, monosaccharides, and disaccharides, and more preferable examples include sucralose, acesulfame salts, Examples include saccharin and its salts, cyclamic acid and its salts, glucose, fructose, honey, isomerized sugar, invert sugar, sucrose, maltose, lactose, lactulose, trehalose, palatinose, and trehalulose, and more preferably sucralose and acesulfame potassium. , glucose, fructose, honey, and sucrose.
本発明の漢方エキス製剤中の甘味料の含有量としては特に限定されず、漢方エキス製剤の剤型により異なりうるが、例えば0.02~0.1重量%、好ましくは0.03~0.08重量%が挙げられる。 The content of the sweetener in the Chinese herbal extract preparation of the present invention is not particularly limited and may vary depending on the dosage form of the Chinese herbal extract preparation, but is, for example, 0.02 to 0.1% by weight, preferably 0.03 to 0.1% by weight. 08% by weight.
本発明の漢方エキス製剤において、漢方エキスの含有量(乾燥エキス換算量)と甘味料の含有量の比率については、上記の各含有量に応じて定まるが、上部消化器症状の副作用の低減効果を高める観点から、漢方エキスの含有量(乾燥エキス換算量)100重量部に対する甘味料の含有量として、好ましくは0.05~2重量部、より好ましくは0.1~1.5重量部、さらに好ましくは0.5~1.2重量部、一層好ましくは0.7~1重量部が挙げられる。 In the Chinese herbal extract preparation of the present invention, the ratio of the content of the Chinese herbal extract (in terms of dry extract) and the sweetener content is determined depending on each of the above contents, but the effect of reducing side effects of upper gastrointestinal symptoms is From the viewpoint of increasing the content of the sweetener, the content of the sweetener is preferably 0.05 to 2 parts by weight, more preferably 0.1 to 1.5 parts by weight, based on 100 parts by weight of the Chinese herbal extract content (in terms of dry extract). More preferably 0.5 to 1.2 parts by weight, even more preferably 0.7 to 1 part by weight.
本発明の漢方エキス製剤において、漢方エキスとして、センキュウ、トウキ、ジオウ、及び/又はマオウを含む漢方のエキスを用いる場合、漢方エキスの抽出に用いられた原生薬中のセンキュウ、トウキ、ジオウ、及びマオウの総量100重量部に対する甘味料の含有量としては、例えば0.01~2.5重量部が挙げられ、上部消化器症状の副作用の低減効果を高める観点から、好ましくは0.05~2重量部、より好ましくは0.1~1.4重量部、さらに好ましくは0.4~1.2重量部が挙げられる。 In the Chinese herbal extract preparation of the present invention, when using a Chinese herbal extract containing Nebula japonica, Angelica japonica, Ephedra, and/or Ephedra as the Chinese herbal extract, the extracts of Chinese herbal medicine containing Lamina japonica, Alcanthus japonica, Ephedra, and/or Ephedra in the original medicine used for extracting the Chinese herbal extract. The content of the sweetener per 100 parts by weight of the total amount of ephedra is, for example, 0.01 to 2.5 parts by weight, and preferably 0.05 to 2 parts by weight from the viewpoint of increasing the effect of reducing side effects of upper gastrointestinal symptoms. Parts by weight, more preferably 0.1 to 1.4 parts by weight, still more preferably 0.4 to 1.2 parts by weight.
その他の成分
本発明の漢方エキス製剤は、上記成分に加え、他の成分として、製剤形態に応じた添加剤や基剤を含んでいてもよい。このような添加剤及び基剤としては、薬学的に許容されることを限度として特に制限されないが、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、等張化剤、可塑剤、分散剤、乳化剤、溶解補助剤、湿潤化剤、安定化剤、懸濁化剤、粘着剤、コーティング剤、光沢化剤、水、油脂類、ロウ類、炭化水素類、脂肪酸類、高級アルコール類、エステル類、水溶性高分子、界面活性剤、金属石鹸、低級アルコール類、多価アルコール、pH調整剤、緩衝剤、酸化防止剤、紫外線防止剤、防腐剤、上記所定の甘味料以外の矯味剤、香料、粉体、増粘剤、色素、キレート剤等が挙げられる。これらの添加剤は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。また、これらの添加剤及び基剤の含有量については、使用する添加剤及び基剤の種類、漢方エキス製剤の製剤形態等に応じて適宜設定される。
Other Components In addition to the above-mentioned components, the Chinese herbal extract preparation of the present invention may contain additives and bases depending on the formulation form as other components. Such additives and bases are not particularly limited as long as they are pharmaceutically acceptable, but include, for example, excipients, binders, disintegrants, lubricants, tonicity agents, plasticizers, Dispersants, emulsifiers, solubilizing agents, wetting agents, stabilizers, suspending agents, adhesives, coating agents, brightening agents, water, oils and fats, waxes, hydrocarbons, fatty acids, higher alcohols , esters, water-soluble polymers, surfactants, metal soaps, lower alcohols, polyhydric alcohols, pH adjusters, buffers, antioxidants, ultraviolet inhibitors, preservatives, flavorings other than the above prescribed sweeteners agents, fragrances, powders, thickeners, pigments, chelating agents, etc. These additives may be used alone or in combination of two or more. Furthermore, the contents of these additives and bases are appropriately set depending on the types of additives and bases used, the formulation form of the Chinese herbal extract preparation, and the like.
また、本発明の漢方エキス製剤は、上記成分に加え、他の成分として、必要に応じて、他の栄養成分や薬理成分を含有していてもよい。このような栄養成分や薬理成分としては、薬学的に許容されることを限度として特に制限されないが、例えば、制酸剤、健胃剤、消化剤、整腸剤、鎮痙剤、粘膜修復剤、抗炎症剤、収れん剤、鎮吐剤、鎮咳剤、去痰剤、消炎酵素剤、鎮静催眠剤、抗ヒスタミン剤、カフェイン類、強心利尿剤、抗菌剤、血管収縮剤、血管拡張剤、局所麻酔剤、生薬エキス、ビタミン類、メントール類等が挙げられる。これらの栄養成分や薬理成分は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。また、これらの成分の含有量については、使用する成分の種類等に応じて適宜設定される。 Moreover, in addition to the above-mentioned components, the Chinese herbal extract preparation of the present invention may contain other nutritional components and pharmacological components as necessary. Such nutritional and pharmacological ingredients are not particularly limited as long as they are pharmaceutically acceptable, but include, for example, antacids, stomachic agents, digestive agents, intestinal regulation agents, antispasmodics, mucosal repair agents, anti-inflammatory agents, and astringents. agents, antiemetics, antitussives, expectorants, anti-inflammatory enzymes, sedative-hypnotics, antihistamines, caffeine, cardiac diuretics, antibacterial agents, vasoconstrictors, vasodilators, local anesthetics, herbal extracts, vitamins, menthol etc. These nutritional components and pharmacological components may be used alone or in combination of two or more. Further, the contents of these components are appropriately set depending on the types of components used.
製剤形態
本発明の漢方エキス製剤の製剤形態については特に限定されないが、具体的な製剤形態としては、例えば、散剤、細粒剤、顆粒剤(ドライシロップを含む)等の固形状製剤;ゼリー剤等の半固形状製剤;液剤、懸濁剤、シロップ剤等の液状製剤が挙げられ、好ましくは液状製剤が挙げられる。本発明の漢方エキス製剤をこれらの製剤形態に調製するには、有効成分である上記所定の漢方エキス、及び必要に応じて添加される添加剤、基剤、及び薬理成分を用いて、通常の製剤化手法に従って製剤化すればよい。
Formulation Form The formulation form of the Chinese herbal extract formulation of the present invention is not particularly limited, but specific formulation forms include, for example, solid formulations such as powders, fine granules, and granules (including dry syrup); jelly formulations, etc. semi-solid preparations; liquid preparations such as solutions, suspensions, and syrups, and preferably liquid preparations. In order to prepare the Chinese herbal extract preparations of the present invention into these formulations, the above-mentioned prescribed Chinese herbal extracts as active ingredients, and additives, bases, and pharmacological ingredients added as necessary, are used in conventional preparations. It may be formulated according to the formulation method.
服用方法
本発明の漢方エキス製剤は、服用時に水に溶いて飲用する。本発明の漢方エキス製剤の1回当たりの用量としては、漢方エキスの乾燥エキス換算量で、例えば0.5~5g、
好ましくは1~4g、より好ましくは2~3.5g、さらに好ましくは2.2~3.3gが挙げられる。また、本発明の漢方エキス製剤の1回当たりの用量としては、漢方エキスの抽出に用いられた原生薬中のセンキュウ、トウキ、ジオウ、及びマオウの総量で、例えば1.5~6g、好ましくは2.2~5g、より好ましくは2.5~4g、さらに好ましくは2.8~3.4gが挙げられ、当該用量を、1日2~3回、好ましくは2回に分けて服用することができる。水の温度としては特に限定されず、例えば10~80℃、好ましくは20~75℃、より好ましくは30~65℃、より好ましくは38~50℃が挙げられる。水に溶くとは、水に完全に溶解させることは要さず、水中に分散させることも含まれる。水の使用量としては、水に溶いた後の希釈漢方エキス製剤中の甘味料の含有量が、0.002~0.02重量%、好ましくは0.005~0.015重量%となる量が挙げられる。
How to Take The Chinese herbal extract preparation of the present invention is dissolved in water and drunk. The dosage of the Chinese herbal extract preparation of the present invention per time is, for example, 0.5 to 5 g in terms of dry extract of the Chinese herbal extract,
Preferably, the amount is 1 to 4 g, more preferably 2 to 3.5 g, and still more preferably 2.2 to 3.3 g. In addition, the dose per dose of the Chinese herbal extract preparation of the present invention is the total amount of Nebula, Ephedra, Ephedra, and Ephedra in the crude drug used for extracting the Chinese herbal extract, for example, 1.5 to 6 g, preferably Examples include 2.2 to 5 g, more preferably 2.5 to 4 g, and still more preferably 2.8 to 3.4 g, and the dose should be taken 2 to 3 times a day, preferably in two divided doses. Can be done. The temperature of the water is not particularly limited, and includes, for example, 10 to 80°C, preferably 20 to 75°C, more preferably 30 to 65°C, and more preferably 38 to 50°C. Solubility in water does not necessarily mean complete dissolution in water, but also includes dispersion in water. The amount of water used is such that the content of the sweetener in the diluted Chinese herbal extract formulation after dissolving in water is 0.002 to 0.02% by weight, preferably 0.005 to 0.015% by weight. can be mentioned.
以下、本発明を実施例により具体的に説明するが、本発明はこれらの実施例に限定されるものではない。 EXAMPLES Hereinafter, the present invention will be specifically explained with reference to Examples, but the present invention is not limited to these Examples.
(1)漢方エキス製剤の調製
(1-1)四物湯エキスの濃縮液
原料生薬として、シャクヤク1.5g、ジオウ1.5g、センキュウ1.5g、及びトウキ1.5gの割合で用い、これらを刻んだ後、水15倍重量を用いて約100℃で1時間抽出し、遠心分離して抽出液を得た。抽出液を減圧下で濃縮し、四物湯エキスの濃縮液の濃縮液を得た。全ての原生薬100重量部から得られた四物湯エキス(乾燥エキス換算量)の量は40重量部である。濃縮液の1日用量は10g(漢方エキスの乾燥エキス換算量2.46g、乾燥漢方エキス2.46gの抽出に用いられた原生薬中のセンキュウ及びトウキの総量は、3.08g)とした。
(1) Preparation of Chinese herbal extract preparation (1-1) Concentrated liquid of Shimotsuto extract As raw materials, 1.5 g of peonies, 1.5 g of rhododendron, 1.5 g of chinensis, and 1.5 g of Japanese acanthus were used as raw materials. After chopping, it was extracted using 15 times the weight of water at about 100°C for 1 hour, and centrifuged to obtain an extract. The extract was concentrated under reduced pressure to obtain a concentrated solution of Shimotsuto extract. The amount of Shimotsuto extract (converted to dry extract) obtained from 100 parts by weight of all the crude drugs was 40 parts by weight. The daily dose of the concentrate was 10 g (2.46 g in terms of dried extract of the Chinese herbal extract, the total amount of Nebula and Angelica in the herbal medicine used to extract 2.46 g of the dried Chinese herbal extract was 3.08 g).
(1-2)独活葛根湯エキスの濃縮液
原料生薬として、カッコン2.5g、ケイヒ1.5g、シャクヤク1.5g、マオウ1.0g、ドクカツ1.0g、ショウキョウ0.167g、ジオウ2.0g、タイソウ0.5g、及びカンゾウ0.5gの割合で用い、これらを刻んだ後、水15倍重量を用いて約100℃で1時間抽出し、遠心分離して抽出液を得た。抽出液を減圧下で濃縮し、独活葛根湯エキスの濃縮液を得た。全ての原生薬100重量部から得られた独活葛根湯エキス(乾燥エキス換算量)の量は30重量部である。濃縮液の1日用量は10g(漢方エキスの乾燥エキス換算量3.14g、乾燥漢方エキス3.14gの抽出に用いられた原生薬中のマオウ及びジオウの総量は、2.94g)とした。
(1-2) Concentrated liquid of Dokatsu Kakkonto Extract The raw materials are 2.5 g of kakkon, 1.5 g of cinnamon bark, 1.5 g of peony, 1.0 g of ephedra, 1.0 g of dokatsu, 0.167 g of ginger, 2. After chopping these, they were extracted at about 100° C. for 1 hour using 15 times the weight of water and centrifuged to obtain an extract. The extract was concentrated under reduced pressure to obtain a concentrated solution of Dokkatsu Kakkonto extract. The amount of Dokatsu Kakkonto extract (converted to dry extract) obtained from 100 parts by weight of all the crude drugs was 30 parts by weight. The daily dose of the concentrate was 10 g (3.14 g in terms of dry extract of the Chinese herbal extract, the total amount of ephedra and rhubarb in the herbal medicine used to extract 3.14 g of the dried Chinese herbal extract was 2.94 g).
(1-3)抑肝散エキスの濃縮液
原料生薬として、トウキ1.5g、チョウトウコウ1.5g、センキュウ1.5g、ビャクジュツ2.0g、ブクリョウ2.0g、サイコ1.0g、及びカンゾウ0.75gの割合で用い、これらを刻んだ後、水15倍重量を用いて約100℃で1時間抽出し、遠心分離して抽出液を得た。抽出液を減圧下で濃縮し、抑肝散エキスの濃縮液を得た。全ての原生薬100重量部から得られた抑肝散エキス(乾燥エキス換算量)の量は24重量部である。濃縮液の1日用量は10g(漢方エキスの乾燥エキス換算量2.7g、乾燥漢方エキス2.7gの抽出に用いられた原生薬中のトウキ及びセンキュウの総量は、3.3g)とした。
(1-3) Concentrated liquid of yokukansan extract As raw materials, 1.5 g of Chinese trumpet, 1.5 g of chotōkou, 1.5 g of chinensis, 2.0 g of sandalwood, 2.0 g of bukryō, 1.0 g of licorice, and 0 g of licorice After chopping them, they were extracted at about 100° C. for 1 hour using 15 times the weight of water and centrifuged to obtain an extract. The extract was concentrated under reduced pressure to obtain a concentrated solution of Yokukansan extract. The amount of Yokukansan extract (converted to dry extract) obtained from 100 parts by weight of all the crude drugs was 24 parts by weight. The daily dose of the concentrate was 10 g (2.7 g in terms of dry extract of the Chinese herbal extract, the total amount of Angelica and Namiki in the crude drug used to extract 2.7 g of the dried Chinese herbal extract was 3.3 g).
(1-4)漢方エキス製剤
上記(1-1)~(1-3)で調製した漢方エキスの濃縮液を用い、表1~4に示す漢方エキス製剤を調製した。
(1-4) Chinese herbal extract preparations Using the concentrated liquids of Chinese herbal extracts prepared in (1-1) to (1-3) above, the Chinese herbal extract preparations shown in Tables 1 to 4 were prepared.
(2)上部消化器症状の副作用の評価
過去に医薬品で胃腸障害を起こしたことがある胃虚弱の被験者45名を、四物湯エキス服用群、独活葛根湯エキス服用群、及び抑肝散エキス服用群の3群(各15名)に振り分け、6週間の間、毎日、上記1日用量を2回に分けて漢方製剤を服用させた。漢方製剤は、用時に、40℃~50℃の水を約100mL(10倍体積量)加え、よくかき混ぜて、空腹時に服用した。なお、各群において、試験期間中は、1週間ごとに、服用する比較例(1種類)又は実施例の漢方エキス製剤(5種類)を変更した。なお、比較例(1種)及び実施例(5種)の漢方エキス製剤を服用する順番は、全ての被験者に対して、ランダムに割り当てた。
(2) Evaluation of side effects of upper gastrointestinal symptoms 45 subjects with gastric weakness who had previously experienced gastrointestinal disorders due to pharmaceuticals were divided into four groups: a group taking Shimotsuto extract, a group taking Dokkatsu Kakkonto extract, and a group taking Yokukansan extract. The subjects were divided into 3 groups (15 people each), and the above daily dose was divided into two doses and the Chinese herbal preparation was administered every day for 6 weeks. When using the Chinese herbal preparation, approximately 100 mL (10 times the volume) of water at 40°C to 50°C was added, mixed well, and taken on an empty stomach. In addition, in each group, during the test period, the Comparative Example (1 type) or the Chinese herbal extract formulation (5 types) of the Example to be taken was changed every week. The order in which the Chinese herbal extract preparations of Comparative Example (1 type) and Example (5 types) were taken was randomly assigned to all subjects.
検体の服用開始から1週間ごとに消化器症状を評価した。具体的には、当該1週間の最後の日に、過去1週間の消化器症状を振り返って評価した。消化器症状の評価は、消化器症状に関する問診票である「出雲スケール」(日本消化器病学会雑誌 2009;106:1478-1487)を用い上部消化器症状(胸やけ、胃痛、胃もたれ)及び下部消化器症状(便秘、下痢)を評価した。出雲スケールは、0~15の数値で消化器症状の程度が評価され、数値が小さいほど症状が軽いことを示す。結果を表1~4に示す。 Gastrointestinal symptoms were evaluated every week from the start of taking the sample. Specifically, on the last day of the week, the digestive symptoms over the past week were reviewed and evaluated. Gastrointestinal symptoms were evaluated using the “Izumo Scale” (Journal of the Japanese Society of Gastroenterology 2009; 106:1478-1487), which is a questionnaire on digestive symptoms. Lower gastrointestinal symptoms (constipation, diarrhea) were evaluated. The Izumo scale evaluates the severity of gastrointestinal symptoms using a number between 0 and 15, with lower numbers indicating milder symptoms. The results are shown in Tables 1 to 4.
表1~3に示す通り、実施例1~15の漢方エキス製剤は、消化器症状の副作用を示す生薬であるセンキュウ、トウキ、ジオウ、及び/又はマオウを含む漢方のエキスを含有しているにも関わらず、所定の甘味料(塩素化糖、スルホンアミド化合物、単糖、二糖)を配合することにより、上部消化器症状を顕著に低減できることが確認できた。なお、表4に示す通り、所定の甘味料とは異なる甘味料を用いた場合は、上部消化器症状の低減効果は認められなかった。つまり、実施例1~15の漢方エキス製剤による上部消化器症状の顕著な低減効果は、所定の甘味料を用いたことによる特有の効果であることが判った。 As shown in Tables 1 to 3, the Chinese herbal extract formulations of Examples 1 to 15 contain extracts of Chinese herbal medicines containing nebula, acanthus, argentina, and/or ephedra, which are herbal medicines that exhibit side effects of gastrointestinal symptoms. Nevertheless, it was confirmed that upper gastrointestinal symptoms can be significantly reduced by incorporating a prescribed sweetener (chlorinated sugar, sulfonamide compound, monosaccharide, disaccharide). As shown in Table 4, when a sweetener different from the predetermined sweetener was used, no effect of reducing upper gastrointestinal symptoms was observed. In other words, it was found that the remarkable reducing effect on upper gastrointestinal symptoms by the Chinese herbal extract formulations of Examples 1 to 15 was a unique effect due to the use of the prescribed sweetener.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022138015A JP2024034027A (en) | 2022-08-31 | 2022-08-31 | Chinese medicine extract formulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022138015A JP2024034027A (en) | 2022-08-31 | 2022-08-31 | Chinese medicine extract formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2024034027A true JP2024034027A (en) | 2024-03-13 |
Family
ID=90193422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022138015A Pending JP2024034027A (en) | 2022-08-31 | 2022-08-31 | Chinese medicine extract formulation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2024034027A (en) |
-
2022
- 2022-08-31 JP JP2022138015A patent/JP2024034027A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9694045B2 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases comprising trachelospermi caulis extract and paeonia suffruticosa andrews extract, and method for preparing the same | |
JPH1036276A (en) | Antiallergic agent and antiallergic cosmetic material and food containing the same | |
EP0370284B1 (en) | A composition containing an extract obtained by a watercontaining organic solvent, and a process for preparing the same | |
Hasan et al. | Effect of fenugreek on type 2 diabetic patients | |
Aslani et al. | Design, formulation and evaluation of Aloe vera chewing gum | |
TW536403B (en) | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy | |
JP2024034027A (en) | Chinese medicine extract formulation | |
JP2021195358A (en) | Kidney function improving agent | |
WO2021005580A1 (en) | Use of a herbal extract comprising verbascoside and aucubin for the treatment of osteoarthritis of the knee | |
FR3005263A1 (en) | PHARMACEUTICAL OR DIETETIC COMPOSITION LIQUID OR SEMI-LIQUID FREE OF AMERTUME CONTAINING SALT OF ARGININE. | |
CN104642869B (en) | A kind of health food with bowel relaxing functions | |
JP2024017078A (en) | Muscle water content improving agent | |
Sharma et al. | A Comparative Pharmaco-Analytical Study of Vyoshadi Gutika and its Modified Dosage Form wsr to Lozenges. | |
JP7368340B2 (en) | Composition for inhibiting phosphodiesterase 5 | |
JP2004026780A (en) | Composition for treatment of general malaise | |
JP7385990B2 (en) | Hypersomnia treatment | |
JP2024015395A (en) | Hydragogue agent | |
JP7408280B2 (en) | Alcohol metabolism improver | |
JP7409938B2 (en) | Premenstrual appetite suppressant | |
JP2023145935A (en) | Takusyato extract preparation | |
WO2001001982A1 (en) | Aminoethanesulfonic acid-containing preparations | |
JP2021119125A (en) | Appetite-regulating hormone secretion normalizing agent | |
JP2024092065A (en) | Lipid eliminant | |
JP2003300887A (en) | Mixture having antiallergic effect and food product containing the same | |
JP2022102838A (en) | Relaxing effect inducer |